Ticker

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (NYSE: LXU) (“LSB,” “we,” “us,” “our,” or the “Company”) today announced results for the first quarter ended March 31, 2026. First Quarter 2026 Results and Recent Highlights Net sales of $169.5 million compared to $143.4 million in the first quarter of 2025 Net income of $19.7 million compared to a net loss of $1.6 million in the first quarter of 2025 Diluted EPS…

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB”) (NYSE: LXU), today announced that it will release its financial results for the first quarter ended March 31, 2026 on April 29, 2026 after the close of the stock market. LSB's management will host a conference call on Thursday, April 30, 2026 at 10:00 am ET / 9:00 am CT to discuss these results. Participating in the call will be Chairman & Chief Executive…

OKLAHOMA CITY--(BUSINESS WIRE)--LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU) today announced that it has appointed Jonathan Z. Ackerman as an independent member of the Board of Directors (the “Board”) effective April 2, 2026. Mr. Ackerman will stand for direct election by shareholders for the first time at the annual meeting of stockholders on May 21, 2026 (the “2026 Annual Meeting”). Mr. Ackerman has…

BEIJING, March 25, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the special committee of its board of directors (the "Special…

LSB Industries is upgraded to buy after strong FY25 results, robust NOL carryforwards, and an optimistic 2026 outlook. LXU reported FY25 revenues up 22.3% YoY and EPS of $0.22, beating estimates, with EBITDA up 25% and further improvements targeted. Substantial NOLs ($243.9M federal, $342.7M state) are protected by a poison pill, enhancing future tax efficiency and takeover defense.